5-chloro-2,3-dihydrophthalazin-1,4-dione | 3790-09-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-chloro-2,3-dihydrophthalazin-1,4-dione
• 英文别名: 5-chloro-2,3-dihydrophthalazine-1,4-dione
• CAS: 3790-09-8
• 化学式: C₈H₅ClN₂O₂
• 分子量: 196.593
• InChiKey: OWSMVNKJAKFZLF-UHFFFAOYSA-N

物化性质

• 密度：
  1.475±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-chloro-2,3-dihydrophthalazin-1,4-dione 在 五氯化磷 、 sodium hydride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 methyl 5-((4,8-dichlorophthalazin-1-yl)oxy)-2-fluorobenzoate
  参考文献：
  名称：

  POLY (ADP-RIBOSE) POLYMERASE INHIBITOR

  摘要：

  揭示了一种邻苯二甲酰肼（邻苯二酮）化合物，以及包含该化合物的药物组合物。作为DNA修复酶聚（ADP-核糖酶）聚合酶抑制剂，该化合物和药物组合物可以有效治疗涉及PARP酶活性的疾病，包括癌症、神经退行性疾病、炎症等。

  公开号：

  US20150051211A1
• 作为产物：
  描述：

  3-氯苯酐 在 盐酸 、 hydrazine hydrate 作用下， 以 喹啉 为溶剂， 反应 24.0h， 生成 5-chloro-2,3-dihydrophthalazin-1,4-dione
  参考文献：
  名称：

  N-氯化诱导的1,4-二甲氧基酞嗪的氧化环收缩

  摘要：

  描述了很少探索的富电子的1,2-二嗪的氧化环收缩。用亲电子氯化试剂（TCICA）处理后，1,4-二甲氧基邻苯二甲azine嗪会经历N-氯化诱导的环收缩，并伴有一个氮原子的损失。用一系列的1，4-二甲氧基邻苯二甲醛衍生物检查了这种异常反应性的范围。另外，基于分离的反应中间体和DFT计算，提出了经由双环物质进行的机理。

  DOI：

  10.1016/j.tetlet.2020.152048

文献信息

• N-Chlorination-induced, oxidative ring contraction of 1,4-dimethoxyphthalazines
  作者：Jeong Kyun Im、ByeongDo Yang、Ilju Jeong、Jun-Ho Choi、Won-jin Chung

  DOI：10.1016/j.tetlet.2020.152048

  日期：2020.6

  A rarely explored oxidative ring contraction of electron-rich 1,2-diazine is described. Upon treatment with an electrophilic chlorinating reagent (TCICA), 1,4-dimethoxyphthalazines undergo an N-chlorination-induced ring contraction that is accompanied by the loss of one nitrogen atom. The scope of this unusual reactivity was examined with a range of 1,4-dimethoxyphthalazine derivatives. In addition

  描述了很少探索的富电子的1,2-二嗪的氧化环收缩。用亲电子氯化试剂（TCICA）处理后，1,4-二甲氧基邻苯二甲azine嗪会经历N-氯化诱导的环收缩，并伴有一个氮原子的损失。用一系列的1，4-二甲氧基邻苯二甲醛衍生物检查了这种异常反应性的范围。另外，基于分离的反应中间体和DFT计算，提出了经由双环物质进行的机理。
• 2,3-dihydrophthalazine-1,4-diones
  申请人：Research Corporation

  公开号：US04861778A1

  公开（公告）日：1989-08-29

  A compound having the structural formula ##STR1## wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 carbalkoxyalkyl or phenyl substituted with C.sub.1 -C.sub.3 alkyl or halogen; R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl; and R.sup.3 and R.sup.4 are the same or different and are hydrogen, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy or halogen with the provisos that if R.sup.2, R.sup.3 and R.sup.4 are hydrogen, then R.sup.1 is not methyl, n-propyl or phenyl substituted with methyl in the ortho or para position; if R.sup.1, R.sup.2 and R.sup.3 are hydrogen then R.sup.4 is not hydrogen, methyl or methoxy; and if R.sup.1 and R.sup.2 are both n-propyl or n-butyl then R.sup.3 and R.sup.4 are not both hydrogen. These compounds demonstrate utility as hypolipidemic agents. The present invention is also directed to a process for controlling hyperlipidemia in mammals comprising treating mammals with a hyperlipidemia controlling effective amount of a compound having the above-identified structural formula wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 carboxyalkyl, C.sub.2 -C.sub.6 carbalkoxyalkyl, phenyl or phenyl substituted with C.sub.1 -C.sub.3 alkyl or halogen; R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl; and R.sup.3 and R.sup.4 are the same or different and are hydrogen, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy or halogen. Yet another aspect of the present invention is embodied in a pharmaceutical composition comprising a compound having the above structural formula wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 carboxyalkyl, C.sub.2 -C.sub.6 carbalkoxyalkyl, phenyl or phenyl substituted with C.sub.1 -C.sub.3 alkyl or halogen; R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl; and R.sup.3 and R.sup.4 are the same or different and are hydrogen, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy or halogen and a pharmaceutically acceptable carrier therefor.

  一种具有结构式##STR1##的化合物，其中R.sup.1是氢、C.sub.1-C.sub.6烷基、C.sub.2-C.sub.6羧基烷基或苯基，所述苯基被C.sub.1-C.sub.3烷基或卤素取代；R.sup.2是氢或C.sub.1-C.sub.6烷基；而R.sup.3和R.sup.4相同或不同，分别是氢、C.sub.1-C.sub.3烷基、C.sub.1-C.sub.3烷氧基或卤素，但有条件，如果R.sup.2、R.sup.3和R.sup.4是氢，则R.sup.1不是甲基、正丙基或苯基，所述苯基被甲基取代于邻位或对位位置；如果R.sup.1、R.sup.2和R.sup.3是氢，则R.sup.4不是氢、甲基或甲氧基；如果R.sup.1和R.sup.2均为正丙基或正丁基，则R.sup.3和R.sup.4不是同时为氢。这些化合物表现出降脂作用。本发明还涉及一种用具有上述结构式的化合物治疗哺乳动物高血脂症的方法，其中R.sup.1是氢、C.sub.1-C.sub.6烷基、C.sub.2-C.sub.6羧基烷基、C.sub.2-C.sub.6羧基烷氧基、苯基或苯基被C.sub.1-C.sub.3烷基或卤素取代；R.sup.2是氢或C.sub.1-C.sub.6烷基；而R.sup.3和R.sup.4相同或不同，分别是氢、C.sub.1-C.sub.3烷基、C.sub.1-C.sub.3烷氧基或卤素。本发明的另一个方面体现在一种制药组合物中，该组合物包括具有上述结构式的化合物，其中R.sup.1是氢、C.sub.1-C.sub.6烷基、C.sub.2-C.sub.6羧基烷基、C.sub.2-C.sub.6羧基烷氧基、苯基或苯基被C.sub.1-C.sub.3烷基或卤素取代；R.sup.2是氢或C.sub.1-C.sub.6烷基；而R.sup.3和R.sup.4相同或不同，分别是氢、C.sub.1-C.sub.3烷基、C.sub.1-C.sub.3烷氧基或卤素，以及其药学可接受的载体。
• Poly (ADP-ribose) polymerase inhibitor
  申请人：CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD.

  公开号：US09187430B2

  公开（公告）日：2015-11-17

  Disclosed are a phthalic hydrazide (phthalazine ketone) compound, and a pharmaceutical composition comprising the same. As a DNA repair enzyme poly (ADP-ribozyme) polymerase inhibitor, the compound and the pharmaceutical composition can effectively treat diseases involving PARP enzymatic activity, including cancer, neural degenerative diseases, inflammation and the like.

  本发明涉及一种邻苯二甲酰肼（邻苯二氮酮）化合物以及包含该化合物的药物组合物。该化合物及药物组合物作为DNA修复酶聚（ADP核糖酶）聚合酶抑制剂，可以有效治疗涉及PARP酶活性的疾病，包括癌症、神经退行性疾病、炎症等。
• AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES
  申请人：Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin

  公开号：EP4279074A1

  公开（公告）日：2023-11-22

  The present invention relates to an azolo compound of Formula I for use in the treatment of fibrosis, wherein the azolo compounds normalizes collagen I mRNA-levels of TGFβ-activated fibroblasts and reverses collagen production to the normal levels that are seen in fibroblasts that are not stimulated.

  本发明涉及一种式 I 的偶氮化合物 其中，该唑基化合物可使 TGFβ 激活的成纤维细胞的胶原蛋白 I mRNA 水平恢复正常，并将胶原蛋白的产生逆转至未受刺激的成纤维细胞的正常水平。
• Persistent, Consistent, Widespread, and Robust? Another Look at Recent Trends in Old-Age Disability
  作者：R. F. Schoeni、V. A. Freedman、R. B. Wallace

  DOI：10.1093/geronb/56.4.s206

  日期：2001.7.1

  Objective. The purpose of this study was to provide new evidence on disability trends among elderly persons from 1982 to 1996.Methods. The sample includes 125,949 participants aged 70 and older in the 1982-1996 National Health Interview Surveys. Logistic analysis was used to estimate the trend in disability prevalence after controlling for various sociodemographic factors.Results. We found that: (a) the prevalence of disability has declined, but the gains did not persist throughout the entire period or accelerate over time: (b) only routine care disability has declined. whereas more severe personal care disability shows no improvements; (c) estimates are robust to the exclusion of the nursing home population but may be sensitive to growth in the assisted living population: (d) estimates of decline in disability prevalence are fairly consistent across five national surveys: (e) gains have been concentrated among the most educated elderly persons: and (F) gains in education appear to be an important confounder of the improvements.Discussion. Evidence from several surveys using various measures indicate that disability has declined among elderly persons. Determining the causes of the improvements should be a high priority in future research efforts.